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ABSTRACT 
Some clinicians avoid amoxicillin-clavulanate (AMC) for the oral therapy of diabetic foot 
infections (DFI), especially for osteomyelitis (DFO), due to its poor bioavailability and bone 
penetration of all antibiotics from the β-lactam class. We performed a retrospective cohort 
analysis among 794 DFI episodes, including 339 DFO cases. The median duration of 
antibiotic therapy after surgical debridement (including partial amputation) was 30 days (DFO 
30 days). Oral AMC was prescribed for a median of 20 days (interquartile range, 12-30 d). 
The median ratio of oral AMC among the entire antibiotic treatment was 0.9 (interquartile 
range, 0.7-1.0). After a median follow-up of 3.3 years, 178 DFIs (22%) overall recurred (DFO 
75; 22%). Overall, oral AMC led to 74% remission compared to 79% with other regimens (χ2-
test; p=0.15). In multivariate analyses and stratified subgroup analyses, oral AMC resulted in 
similar clinical outcomes to other antimicrobial regimens; either when used orally from the 
start, after an initial parenteral therapy, or when prescribed for DFOs. We conclude that oral 
AMC is a reasonable option when treating patients with DFIs and DFOs.  
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Introduction 
Many authorities on orthopedic infections avoid oral β-lactam antibiotics for the post-surgical 
treatment of implant-related orthopedic infections or chronic osteomyelitis
1
 because of poor 
bioavailability and bone penetration concerns
2
. Per analogic consequence, experts argue also 
often against oral β-lactam agents for diabetic foot infections (DFI), especially when bone 
(DFO) is involved
1,2
, although this avoidance of β-lactams is not ubiquitous. There might be 
countries or settings lacking this particular concern.  
For DFI, there is a great variability in antibiotics used by clinicians, but amoxicillin/clavulanic 
acid (AMC) is among the most frequently administered oral β-lactam for DFI worldwide2-4. 
Major practice-oriented guidelines, such as those of the Infectious Diseases Society of 
America (IDSA)
5
 and the International Working Group on the Diabetic Foot (IWGDF)
6
 
suggest that oral AMC works for mild and moderate DFI. However, despite widespread 
potential implications in daily clinical life, scientific clinical data concerning this particular 
question are non-existing and the literature needs scientific confirmation regarding the use or 
avoidance of oral β-lactams, in particular AMC, for DFI. Therefore, we conducted the first 
large single-center cohort study on this topic. 
 
Methods 
The Geneva University Hospitals has been running a clinical pathway for adult DFI patients 
from March 2013 to March 2018. As a part of a quality assurance program, patients were not 
required to provide informed consent
7
. Our DFI definitions based on the IDSA guidelines
5
 
requiring two signs of local inflammation and pathogens in two intraoperative tissue samples. 
We diagnosed diabetic foot osteomyelitis (DFO) by a combination of clinical features (e.g., 
visible bone) plus imaging (bone lesions without prior surgery or trauma); and/or 
microbiological results (bacteria on several intraoperative bone cultures). We excluded major 
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amputations and only included DFOs if there was residual osteitis after surgery. We defined 
remission as the absence of clinical, laboratory or imaging evidence of the original infection 
after a minimum follow-up of two months. Of note, in our region oral AMC covers most DFI 
pathogens for at least 70%, including anaerobes such as Bacteroides fragilis.  
 
Results 
We followed 794 first DFI episodes (419 patients; 220 females; median age 69 years) for a 
median duration of 3.3 years after treatment. A total of 241 patients (57.5%) revealed one DFI 
episode, 178 had between two and 12 DFI new “first” episodes. During the five-year study 
period, 74 patients died for reasons other than DFIs after the minimal follow-up time. Their 
death was unrelated to infection and thus we kept them in the analyses. Fourteen patients 
(3%) had an immune-suppressive condition other than diabetes (dialysis, cancer, advanced 
cirrhosis, or medication-related). In 19% of the episodes an antibiotic therapy within the last 
two weeks influenced the intraoperative cultures. Intraoperative cultures revealed 107 
different constellations of microorganisms. The most frequent pathogens were Staphylococcus 
aureus (n=273; of which 61 methicillin-resistant), streptococci (121), and gram-negatives 
(269). According to the IDSA criteria
5
, we revealed oft tissue DFIs were graded upon the with 
81 mild soft tissue DFIs, 587 moderate and 126 severe DFIs, while the 339 DFO episodes 
(43%) mostly occurred in the forefoot with less hindfoot (8%) or ankle (9%) involvement.  
 
Therapy 
The median number of surgical debridements per episode was 1 (range, 0-7 surgeries). We 
debrided all DFOs in the operating theatre; along with partial toe amputations. The median 
duration of post-surgical systemic antibiotic therapy was 30 days (DFO 30 days), with a 
median of five days parentally (DFO six days). We used 141 different antibiotic regimens, 
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with changes during their treatment course. In total, we treated 295 DFI episodes with a single 
agent, 186 with two, 125 with three, 41 with four and 20 with five antimicrobial agents. The 
most frequently prescribed drug classes, other than β-lactams, were: quinolones (n=204); 
glycopeptides (120); clindamycin (84); co-trimoxazole (37); and, rifampicin (14).  
 
Overall, we used β-lactams in 631 DFI episodes (79%) including as intravenous therapy and 
partial oral therapy. Among the oral β-lactam agents, AMC (500 mg amoxicillin & 125 mg 
clavulanic acid or 875 mg amoxicillin & 125 clavulanic acid) was the most frequent occurring 
in 301 cases. We administered it during a median of 20 days (interquartile range, 12-30 d; 
DFO 22 days); corresponding to a median ratio of 0.9 between AMC among all other oral 
medications (interquartile range, 0.7-1; ratio in DFO 0.9). In 77 episodes, the entire antibiotic 
therapy consisted of oral AMC (DFO 26 cases). The daily dosing of AMC were 1000 mg bid, 
625 mg tid, or 1000 mg tid, with a median of 2000 mg (interquartile range, 1875-2500 mg 
including for DFO). Of note, no oral AMC therapy was changed or stopped because of severe 
adverse events, while small cutaneous mycosis and diarrheas required additional medication 
in a minority of patients.  Finally, in 234 cases (29%) angiologists revascularized the limb, 95 
episodes underwent hyperbaric oxygen therapy of 30 sessions each, and we instructed all 
patients in proper pressure offloading measures. 
 
Outcomes 
After a median delay of 7.5 months after the end of therapy, 178 (178/794; 22%) DFI 
episodes recurred (DFO 75; 22%). Outcomes with oral AMC therapy were not different from 
other agents overall, including for DFOs (Table 1). Oral AMC led to 74% remission 
(131/178) compared to 79% (485/616) in non-β-lactam regimens (χ2-test; p=0.15). The 
corresponding incidences in the subset of DFO cases were 81% (215/261) versus 80% 
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(60/75), respectively. In view of the considerable case-mix, we adjusted with a Cox regression 
analysis (Table 2 left column). We confirmed that oral AMC therapy achieved the same 
remission, either when administered from the start (hazard ratio 0.9, 95%CI 0.5-1.6), or when 
calculated as absolute numbers of treatment days (HR 1.0, 95%CI 0.9-1.1). These results were 
also consistent for the subset of DFOs (Table 2 right column). 
 
Discussion 
In our DFI cohort, oral AMC therapy did not influence remission. This finding was 
irrespective of whether we treated DFOs or soft tissue infections, from the start or after initial 
parenteral administration, irrespective of alterations of the its standard dosing, when 
computed as a ratio of the entire course or analyzed as absolute numbers of treatment days; or 
when compared with non-betalactam agents. Our study strengths are its size and a well-
defined cohort of patients with a close follow-up. On the basis of a conservative estimate of 
20% failures when treating DFI
2
, our 794 DFI episodes (one of the largest databases), yielded 
the necessary sample size to detect a 7% difference in a superiority design, or a 10% 
difference in a non-inferiority analysis. A randomized trial designed for detecting smaller 
differences requires more than thousand patients, which is clinically impracticable. 
 
From a pharmacological point of view, all β-lactams penetrate poorly into bone. In vitro, the 
reported penetrations vary widely, even for the same molecule
8
. For example, the average 
bone-to-serum ratios vary up to three-fold for amoxicillin and 25-fold for clavulanic acid
8
. 
Even when administered parenterally, β-lactams may reveal a bone-to-serum ratio as low as 
20%
8
. In contrast and clinically speaking, many case series advocate the effectiveness of oral 
AMC therapy for osteomyelitis, such as jaw or skull base osteomyelitis
9
. To cite further 
clinical examples, Sayana et al. successfully treated vertebral osteomyelitis with AMC for 
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eight weeks
10
. Bassey reported an 83% success in 44 post-surgical cases staphylococcal 
osteomyelitis with only five days of parenteral AMC, followed by six weeks of oral AMC
11
. 
Bell reported a successful therapy for 19 adult patients with high-dose oral penicillins for 
staphylococcal osteomyelitis
12
. Hodkin published the remission in 10 of 14 similar patients 
with chronic staphylococcal osteomyelitis
13
. In the pediatric population, several studies in the 
1980’ties supported the effectiveness of oral β-lactam care for acute osteomyelitis10. 
 
In a study specifically addressing DFIs (including 26 DFO cases), Lipsky et al. performed a 
randomized multicenter trial on 108 patients comparing two different regimens
14
. Enrollees 
were allocated into one week of parenteral antibiotic therapy, followed by two weeks of either 
oral quinolones or oral AMC, at standard doses. The clinical remission risk was 85% versus 
83%, respectively, a success rate in line with most published DFI studies
3
. Lazaro-Martinez et 
al. randomized DFO patients to conservative antibiotic treatment (for 90 days) or surgical 
resection plus antibiotics for 10 days
15
. In the antibiotic arm, oral agents were given from the 
start (24 cases with oral AMC 1000 mg bid; 24 cases with other oral antimicrobials). All 
outcomes were equal. Moreover, several guidelines and practice-oriented expert reviews 
recommend oral AMC in DFI, at least in mild cases
2-6
. Finally, Senneville et al. found that the 
only factor predicting success in DFOs would be the susceptibility of the organism to the 
antibiotic employed. No other factor, including bone antibiotic penetration mattered
16
. 
 
In conclusion, we believe that our clinical data, along with the literature and authoritative 
guidelines
5
, suggest that oral AMC is a reasonable option when treating patients with DFIs 
and DFOs. 
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Table 1 - Characteristics of patients with diabetic foot osteomyelitis without major amputation 
 Clinical remission  Clinical failure 
n = 339 n = 264 p value* n = 75 
Female sex 78 (30%) 0.16 16 (21%) 
Age (median) 70 years 0.08 65 years 
Insulin therapy 157 (66%) 0.42 47 (71%) 
Bacteremia 26 (11%) 0.42 5 (8%) 
First episode of diabetic foot 
osteomyelitis 
135 (51%) 0.34 43 (57%) 
Number of past infection 
episodes (median) 
1 0.18 1 
Number of surgical 
interventions (median) 
1 (range, 0-2) 0.30 1 (range, 0-6) 
Hyperbaric oxygen therapy 31 (12%) 0.71 10 (13%) 
Duration of antibiotic 
treatment (median) 
30 days 0.68 31 days 
Duration of intravenous 
antibiotics (median) 
6 days 0.37 5 days 
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rti
cl
e
 
Signif
icant 
p 
value
s ≤ 
.05 
(two-
tailed
) are 
displ
ayed 
in 
bold 
and italic. Pearson-χ2 and Wilcoxon-ranksum-tests, as appropriate 
 
Oral co-amoxiclav for the 
entire course 
18 (7%) 0.54 7 (9%) 
Duration of oral co-amoxiclav 
(median) 
21 days 0.32 23 days 
Ratio co-amoxiclav/ oral 
therapy (median) 
0.8 0.50 0.9 
Median dose of oral co-
amoxiclav 
2000 mg 0.89 2000 mg 
Non co-amoxiclav therapies 215 (81%) 0.78 60 (80%) 
Use of oral rifampicin 17 (6%) 0.64 6 (8%) 
Revascularization 81 (31%) 0.11 16 (21%) 
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Table 2 - Univariate and multivariate analyses with the outcome “remission,” stratified by 
osteomyelitis (cluster-controlled Cox regression; hazard ratios, with 95% confidence intervals) 
 
n = 794, all 
episodes 
  n = 339, only 
osteomyelitis  
 
Univariate Multivariate Variable Univariate Multivariate 
0.7, 0.5-1.1 0.8, 0.7-1.2 Female sex 0.7, 0.4-1.2 n.d. 
1.0, 1.0-1.0 n.d. Age (continuous) 1.0, 1.0-1.0 1.0, 0.9-1.1 
1.0, 0.9-1.2 1.1, 0.8-1.5 - Age > 60 years 1.4, 0.9-2.5 n.d. 
0.9, 0.5-1.4 n.d. Immune-
suppression* 
n.d. n.d. 
1.3, 0.9-1.8 n.d. Insulin therapy n.d. n.d. 
1.2, 0.9-1.6 1.4, 0.9-1.9 Bacteremia 0.7, 0.3-1.8 n.d. 
1.0, 0.9-1.1 1.0, 0.9-1.1 First episode of 
infection 
1.1, 0.9-1.3 n.d. 
1.0, 0.7-1.6 n.d. More than three 
past episodes 
0.4, 0.2-1.1 n.d. 
1.0, 0.9-1.1 1.1, 0.9-1.2 Number of past 
episodes 
0.8, 0.7-1.1 0.8, 0.5-1.2 
0.9, 0.8-1.1 1.1, 0.8-1.5 Presence of 
osteomyelitis 
n.d. n.d. 
0.9, 0.6-1.2 1.1, 0.7-1.8 - Calcaneal 
osteomyelitis 
0.9, 0.6-1.2 n.d. 
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0.9, 0.8-1.1 1.0, 0.8-1.1 Number of surgeries 0.9, 0.7-1.2 0.9, 0.4-1.9 
0.7, 0.6-0.9 1.0, 0.7-1.4 - (partial) 
amputation 
n.d. n.d. 
1.0, 1.0-1.0 n.d. Use of vacuum-
assistance 
1.0, 0.9-1.1 n.d. 
n.d. n.d. Use of hyperbaric 
oxygen 
1.9, 0.9-3.8 n.d. 
n.d. n.d. Use of hyperbaric 
oxygen therapy 
1.2, 0.5-3.2 1.3, 0.7-2.2 
1.0, 1.0-1.0 1.0, 0.9-1.1 Duration of total 
antibiotics 
1.0, 1.0-1.0 1.0, 1.0-1.0 
1.0, 1.0-1.0 1.0, 0.9-1.1 Duration of 
parenteral 
antibiotics 
1.0, 1.0-1.0 n.d. 
0.8, 0.5-1.1 n.d. Oral rifampicin 0.9, 0.4-2.1 n.d. 
1.2, 1.0-1.5 0.9, 0.5-1.6 Oral co-amoxiclav 
entirely 
2.2, 1.0-4.9 1.5, 0.5-4.7 
1.0, 0.9-1.1 1.0, 0.9-1.1 Duration of oral co-
amoxiclav use  
1.0, 0.9-1.1 1.0, 0.9-1.1 
0.4, 0.5-4.3 0.4, 0.1-3.6 Ratio between 
duration of oral co-
amoxiclav/entire oral 
course 
n.d. n.d. 
1.0, 0.9-1.1 1.0, 0.9-1.1 Median dose of co-
amoxiclav 
1.0, 0.9-1.1 1.0, 0.9-1.1 
1.0, 0.7-1.4 1.0, 0.7-1.3 Revascularisation 0.7, 0.4-1.3 n.d. 
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n.d. = not done 
* Immune-suppression beyond that of diabetes mellitus = Active cancer, dialysis, cirrhosis CHILD C, 
untreated HIV disease and immunosuppressive drugs > equivalent of 15 mg prednisolone par day 
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